Dergiler / Turkish Journal of Pediatrics / 2021 / Cilt: 63 - Sayı: 4

Cost of illness of RSV infection in a middle-income tropical country

Sayfa
673–682
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models, and help guide prevention strategies against RSV.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Despite the burden of disease of Respiratory syncytial virus (RSV) infection in children, there are important gaps in knowledge about the potential impact in terms of health as well as social and healthcare resources.
📊
Temel Bulgular & Veri:The mean cost per patient with an RSV infection was US$ 178.35 CI 95% (30.7-541.67 US$).
💡
Sonuç & Katkı:Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models, and help guide prevention strategies against RSV.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background. Despite the burden of disease of Respiratory syncytial virus (RSV) infection in children, there are important gaps in knowledge about the potential impact in terms of health as well as social and healthcare resources. The aim of this study was to describe the economic burden of RSV in the first two years of life in Colombia. Methods. We conducted a cost-of-illness study, taking a population prevalence-based approach. A decision tree model was constructed with a time horizon of two years. We defined the following outcomes: death, RSV infection with long term complications, RSV with acute complications, RSV without complications. Inpatient and outpatient costs were collected directly from medical invoices of patients who attended a tertiary referral hospital. Results. The mean cost per patient with an RSV infection was US$ 178.35 CI 95% (30.7-541.67 US$). The total cost of RSV infection in children less than 2 years in Colombia was US $ 64 443 616 per year (CI 95% US$11 092 902 – US$195 722 867). In the probabilistic sensitivity analysis, the mean cost per patient with RSV infection was only sensitive to changes in the cost of recurrent wheezing, cost of outpatient visits and cost of hospitalizations. Conclusion. The infection by RSV in Colombia generates a high economic burden on the health system. Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models, and help guide prevention strategies against RSV.

🔖

Bu Makaleye Atıf Yap

PATINO, D. G., SINISTERRA, D., BUENDIA, J. A. (2021). Cost of illness of RSV infection in a middle-income tropical country. Turkish Journal of Pediatrics, Cilt: 63 - Sayı: 4, 673–682. https://ajindex.com/articles/411963

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Shi T, McAllister DA, O’Brien KL, et al; RSV Global Epidemiology Network.Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390: 946-958
  2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-1555
  3. Drysdale SB, Sande CJ, Green CA, Pollard AJ. RSV vaccine use--the missing data. Expert Rev Vaccines 2016; 15: 149-152
  4. Zepeda TJ, Vasquez ZJ, Delpiano ML. Direct costs of low respiratory infection due to RSV in children under one year. Rev Chil Pediatr 2018; 89: 462-470
  5. Kramer R, Duclos A, Lina B, Casalegno JS; VRS study group in Lyon. Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France. Vaccine 2018; 36: 6591-6593
  6. Mac S, Sumner A, Duchesne-Belanger S, Stirling R, Tunis M, Sander B. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: a systematic review. Pediatrics 2019; 143: e20184064
  7. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22: 275-284
  8. Barbosa Ramirez J, Pulido Dominguez P, Rey Benito G, Mendez Rico J, Castellanos J, Páez Martinez A.Human respiratory syncytial virus and metapneumovirus in patients with acute respiratory infection in Colombia, 2000-2011. Rev Panam Salud Publica 2014; 36: 101-109
  9. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004; 9: 110-118
  10. Bereza BG, Machado M, Papadimitropoulos M, Sproule B, Ravindran AV, Einarson TR. A markov model approach assessing the cost of illness of generalized anxiety disorder in Canada. Neurol Ther 2012; 1: 1
  11. Shah NT, Wright KN, Jonsdottir GM, Jorgensen S, Einarsson JI, Muto MG. The feasibility of societal cost equivalence between robotic hysterectomy and alternate hysterectomy methods for endometrial cancer. Obstet Gynecol Int 2011; 2011: 570464
  12. Furiak N, Klein RW, Gahn JC, Camber SB, Summers K. Use of a decision tree model to estimate the economic benefits of reducing schizophrenia illness relapse. Value Health 2013; 16: A62-A63
  13. Barbosa J, Parra B, Alarcon L, Qu